4//SEC Filing
Peetz Christopher 4
Accession 0001415889-25-006524
CIK 0001759425other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:26 PM ET
Size
11.5 KB
Accession
0001415889-25-006524
Insider Transaction Report
Form 4
Peetz Christopher
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
2025-03-03$46.61/sh−19,392$903,861→ 136,528 total - Exercise/Conversion
Common Stock
2025-03-03$2.94/sh+40,000$117,440→ 155,920 total - Sale
Common Stock
2025-03-03$47.19/sh−20,608$972,492→ 115,920 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-03-03−40,000→ 238,487 totalExercise: $2.94Exp: 2029-03-11→ Common Stock (40,000 underlying)
Holdings
- 208,570(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on November 22, 2024.
- [F2]The weighted average sale price for the transaction reported was $46.61, and the range of prices were between $45.82 and $46.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $47.19, and the range of prices were between $46.82 and $47.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F4]The stock option is fully vested.
Documents
Issuer
Mirum Pharmaceuticals, Inc.
CIK 0001759425
Entity typeother
Related Parties
1- filerCIK 0001614740
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:26 PM ET
- Size
- 11.5 KB